Study Found That Long Term Use Of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss In Patients With COPD GlaxoSmithKline (NYSE: GSK) announced that data from a three-year study of patients with Chronic Obstructive Pulmonary Disease (COPD) found that the inhaled corticosteroid in Advair Diskus 250/50, fluticasone propionate, did not show an adverse effect on bone mineral density (BMD) measured at the lumbar spine and total hip compared to salmeterol alone.
Source: www.medicalnewstoday.comImClone Announces ERBITUX(R) Commercial Launch In Canada For Advanced Colorectal Cancer ImClone Systems Incorporated (NASDAQ: IMCL) today announced the commercial launch of ERBITUX® (cetuximab) in Canada for use in the treatment of metastatic colorectal cancer (mCRC). Bristol-Myers Squibb collaborates with ImClone on ERBITUX in North America and is making the product commercially available through its wholly-owned subsidiary Bristol-Myers Squibb Canada.
Source: www.medicalnewstoday.comDeputy Director From The FDA's Office Of Critical Path Programs To Deliver Rare Address At Clinical Trials Congress The Institute for International Research is pleased to announce a featured presentation by Leonard Sacks, Deputy Director of the Office of Critical Path Programs from the US Food & Drug Administration (FDA) at the 7th annual Clinical Trials Congress (CTC). Dr. Sacks will illuminate how key stakeholders in public
health and drug development should be forming partnerships with the FDA to advance the critical path to drug development. Dr.
Source: www.medicalnewstoday.comAnimal Testing - MEP Wants Law Changed, Duplicate Experiments Mean Too Many Animals Suffering, Europe Plaid MEP Jill Evans (Wales) believes a twenty year old European law on animal testing is in urgent need of updating because it allows too many animals to suffer unnecessarily. The MEP says many experiments are being duplicated, leading to animal suffering that could be avoided. The MEP wants the European Commission to establish a Europe-wide database, accessible to researchers, to help reduce the number of animals suffering in experiments.
Source: www.medicalnewstoday.comMembrane Fusion At The Synapse: Janus Faced Synaptotagmin-1 Helps To Keep The Fast Pace Imagine a bathtub with two soap bubbles colliding but never fusing. Then you add detergent, and the surface of the water goes flat as the walls of the bubbles collapse and merge. Dr.
Source: www.medicalnewstoday.comRexin-G Returns To The Big Apple: Clinical Trials For Pancreatic Cancer And Breast Cancer Open In Manhattan Epeius Biotechnologies Corporation announced the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic
medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.
Source: www.medicalnewstoday.comIntegrating Mental Health, Substance Abuse, And Primary Medical Care Appears Promising, But More Research Is Needed A new report released today by HHS' Agency for
Healthcare Research and Quality found evidence that people treated for depression in primary care clinics that provide coordinated services for mental and physical
health do better and have fewer symptoms than patients who are treated at sites that just provide
health services.
Source: www.medicalnewstoday.comGlaxoSmithKline To Acquire Genelabs Technologies To Increase Focus On Novel Small Molecule Therapies For Hepatitis C GlaxoSmithKline (LSE:GSK)(NYSE:GSK) and Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).
Source: www.medicalnewstoday.comFDA Awards NIPTE 1.19 Million Dollars Contract To Develop Quality By Design (QbD) Guidance Elements The U.S. Food and Drug Administration (FDA) has awarded the National Institute for Pharmaceutical Technology and Education (NIPTE) a contract to develop Quality by Design guidance on design space specifications. The intention of this award is development of specifications allowing for the implementation of Quality by Design (QbD) framework to improve product quality through science and technology.
Source: www.medicalnewstoday.com
# posted by Network @ 1:00 PM
